Rockwell Medical

Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. Its products include Triferic, CitraPure, RenalPure and SteriLyte. The company was founded by Robert L. Chioini in January 1995 and is headquartered in Wixom, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Rockwell Medical reports record revenue and eyes global expansion

Rockwell Medical's Q4 2022 earnings call showcased strong revenue growth, operational improvements, and strategic initiatives for future profitability. While challenges in expense optimization and debt reduction persist, the company's focus on growth through international partnerships and new product developments presents promising opportunities. Overall, Rockwell Medical is on track to achieve financial stability and sustained growth in the healthcare market.

Rockwell Medical reports record revenue and progress towards profitability

Rockwell Medical (RMTI) delivered strong Q1 2023 results with record revenue and progress towards profitability. The company's strategic initiatives, including the successful transition of the Baxter business, are driving growth. Despite challenges, Rockwell Medical's focus on cost reduction and business development positions it well for future success.

Rockwell Medical reports Q2 challenges but eyes profitability in 2024

Rockwell Medical's Q2 2023 performance reflects challenges in net sales and profitability but highlights strategic progress towards financial stability and growth.
The company's strengths lie in revenue increase, expense reduction, and the acquisition of Evoqua's business, positioning it for accelerated profitability.
While facing challenges in financial results and product development, Rockwell's focus on market expansion and optimization presents opportunities for future growth and revenue diversification.

Rockwell Medical posts record Q3 sales, eyes profitability in Q4

Rockwell Medical's Q3 performance reflects strong sales growth and strategic acquisitions.
While facing margin challenges, the company's focus on profitability and leadership enhancements bode well.
Opportunities lie in market dominance, operational improvements, and leveraging customer agreements.
Maintaining financial stability and pursuing growth avenues are key priorities for Rockwell's future success.

Rockwell Medical achieves historic profitability and projects strong sales growth

Rockwell Medical's Q4 2023 performance reflects significant milestones with profitability achieved and record net sales reported. The company's strategic focus on operational efficiency, growth projections, and margin improvements indicate a positive trajectory. While challenges persist, Rockwell is well-positioned to leverage opportunities for sustained growth and profitability.

Rockwell Medical reports record Q1 sales and profitability growth

Rockwell Medical delivered robust financial results in Q1 2024, showcasing growth in net sales, gross profit, and improved profitability metrics.
The company's strategic initiatives to enhance margins, optimize operations, and reduce debt position it well for future growth and value creation.
While facing challenges in a competitive market, Rockwell's unique market position and financial discipline provide a solid foundation for sustained success.

Rockwell Medical reports record-high sales and profitability, eyes global expansion

Rockwell Medical's Q3 2024 performance reflects strong financial health, profitability, and record-high sales, underpinned by strategic initiatives and partnerships.
The company faces challenges in customer dynamics but is well-positioned to capitalize on growth opportunities in at-home dialysis and international markets.
With a focus on quality, customer service, and sustainable profitability, Rockwell Medical is poised for continued success and market expansion.
Overall, Rockwell Medical's Q3 2024 earnings call highlights resilience, adaptability, and a positive outlook for future growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. Its products include Triferic, CitraPure, RenalPure and SteriLyte. The company was founded by Robert L. Chioini in 1996 and is headquartered in Wixom, MI.

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will be the exclusive supplier of all dry hemodialysis concentrates products to Nephro Group.

Rockwell Medical Expands Distribution in the Philippines

Despite a 39% stock drop yesterday, Rockwell Medical's strong Q3 results and upcoming catalyst provide a solid buying opportunity for risk-takers. The stock's dip was due to reduced orders from its largest customer, but Rockwell is diversifying its customer base and entering the at-home dialysis market. Strategic initiatives, including new supply contracts and product line growth, are expected to mitigate revenue reductions and generate future growth.

Rockwell Medical's Dip Gives A Speculative Opportunity

Rockwell Medical, Inc. (NASDAQ:RMTI ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Heather Hunter - Senior Vice President & Chief Corporate Affairs Officer Mark Strobeck - President & Chief Executive Officer Jesse Neri - Senior Vice President of Finance Conference Call Participants Anthony Venditti - Maxim Group Operator Good morning and welcome to Rockwell Medical's Third Quarter 2024 Results Conference Call and Webcast. Please note, this event is being recorded.

Rockwell Medical, Inc. (RMTI) Q3 2024 Earnings Call Transcript

Rockwell Medical (RMTI) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to loss of $0.07 per share a year ago.

Rockwell Medical (RMTI) Surpasses Q3 Earnings and Revenue Estimates

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical today announced financial and operational results for the three and nine months ended September 30, 2024.

Rockwell Medical Reports Third Quarter 2024 Earnings, Generates Profitability on a Cash Flow and Adjusted EBITDA Basis for the Second Consecutive Quarter

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--UPDATED Q3'24 EARNINGS DATE: Rockwell Medical will release its third quarter 2024 financial and operational results on November 12, 2024.

Rockwell Medical Announces Date Change for Third Quarter 2024 Earnings Conference Call and Webcast

Rockwell Medical expects its Q3 results to gain from a high rate of customer conversions toward it compared with its primary competitor.

RMTI Stock Rises 138% in Q3: What Should You Do Ahead of Earnings?

This year can be regarded as a momentous period for RMTI's business because this is the first time in its history that it has achieved steady revenue growth.

Rockwell Medical on Expansion Spree: Should You Buy the Stock Now?

Rockwell Medical (RMTI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Rockwell Medical (RMTI) Upgraded to Buy: Here's Why

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will release its financial and operational results for the third quarter ended September 30, 2024 on Monday, November 11, 2024.

Rockwell Medical to Release Third Quarter 2024 Results on Monday, November 11, 2024

Rockwell Medical (RMTI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Rockwell Medical, Inc. (RMTI) Hits Fresh High: Is There Still Room to Run?

RMTI continues to outperform its peers, banking on its focus on optimizing business to drive sustainable profitability and meaningful cash flow generation.

Rockwell Medical Stock Surges 108.5% YTD: Should You Snap it Up Now?

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Great Place to Work and Fortune magazine selected Rockwell Medical for the 2024 Fortune Best Workplaces in Manufacturing and Production List.

Rockwell Medical Named a Fortune 'Best Workplaces in Manufacturing & Production'

Rockwell develop concentrates for hemodialysis, which is a process that seeks to artificially replace kidney function in patients with chronic failure. Despite being a critical product, there's currently no large competitor dominating the category and the company is a leader. After years of constant CEO turnover and poor results, Mr. Mark Strobeck has turned around and has already reached its first profitable quarter ever.

Rockwell Medical: The Turnaround Is Looking Real

Does Rockwell Medical (RMTI) have what it takes to be a top stock pick for momentum investors? Let's find out.

Rockwell Medical (RMTI) is a Great Momentum Stock: Should You Buy?

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Rockwell Medical (RMTI) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Why Fast-paced Mover Rockwell Medical (RMTI) Is a Great Choice for Value Investors

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical announces a product purchase agreement with the leading at-home and acute care dialysis provider in the United States.

Rockwell Medical Announces Product Purchase Agreement with Leading At-Home and Acute Care Dialysis Provider

Rockwell Medical, Inc. (RMTI) Hit a 52 Week High, Can the Run Continue?

Fast-paced Momentum Stock Rockwell Medical (RMTI) Is Still Trading at a Bargain

Rockwell Medical, Inc. (RMTI) Q2 2024 Earnings Call Transcript

Rockwell Medical (RMTI) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to loss of $0.18 per share a year ago.

Rockwell Medical (RMTI) Tops Q2 Earnings and Revenue Estimates

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical today announced financial and operational results for the three and six months ended June 30, 2024.

Rockwell Medical Reports Profitability on a Cash Flow and Adjusted EBITDA Basis in the Second Quarter of 2024

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical's Convenience Pack offers a number of advantages for home hemodialysis patients and acute care dialysis facilities.

Rockwell Medical Launches Convenience Pack to Support Home Hemodialysis and Acute Dialysis Facilities

Rockwell is a microcap manufacturer of hemodialysis concentrates for kidney failure patients, trading at under 1x full-year 2023 revenue. The company has a significant market opportunity with the growing number of kidney failure patients and potential for expansion into the home dialysis market. Despite a discounted valuation, Rockwell's growth trajectory, focus on profitability, and management execution make it a compelling investment with substantial upside potential.

Rockwell Medical Looks Like A Speculative Buy As It Approaches Profitability

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical's president and CEO, Dr. Mark Strobeck, to present at the H.C. Wainwright 3rd Annual Kidney Conference.

News for Rockwell Medical Stock (RMTI)